Jeffrey M Peters Selected Research

PPAR delta

4/2009	PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
9/2008	Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway.
9/2007	Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene.
5/2006	PPARdelta status and mismatch repair mediated neoplasia in the mouse intestine.
2/2006	PPARdelta regulates glucose metabolism and insulin sensitivity.
11/2005	Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis.
11/2004	PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine.
5/2004	Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey M Peters Research Topics

Disease

43	Neoplasms (Cancer) 11/2019 - 01/2003
38	Carcinogenesis 01/2019 - 12/2002
16	Inflammation (Inflammations) 01/2020 - 09/2004
8	Insulin Resistance 01/2021 - 05/2004
8	Obesity 11/2019 - 05/2004
8	Colonic Neoplasms (Colon Cancer) 11/2011 - 05/2004
6	Skin Neoplasms (Skin Cancer) 01/2019 - 12/2008
5	Hepatomegaly 01/2021 - 10/2004
5	Liver Neoplasms (Liver Cancer) 01/2017 - 11/2004
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2013 - 05/2004
4	Necrosis 01/2021 - 07/2009
4	Body Weight (Weight, Body) 10/2017 - 05/2004
4	Hyperplasia 04/2009 - 02/2006
4	Adenoma (Adenomas) 09/2007 - 01/2005
3	Carcinoma (Carcinomatosis) 01/2018 - 09/2004
3	Breast Neoplasms (Breast Cancer) 04/2014 - 01/2008
3	Dyslipidemias (Dyslipidemia) 12/2009 - 01/2006
3	Hepatocellular Carcinoma (Hepatoma) 03/2009 - 09/2003
3	Polyps 12/2007 - 05/2004
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2021 - 10/2004
2	Neoplasm Metastasis (Metastasis) 10/2018 - 07/2007
2	Melanoma (Melanoma, Malignant) 10/2017 - 01/2008
2	Atherosclerosis 01/2016 - 12/2002
2	Disease Progression 02/2014 - 11/2005
2	Cholestasis 07/2013 - 01/2005
2	Chemical and Drug Induced Liver Injury 02/2013 - 01/2008
2	Type 2 Diabetes Mellitus (MODY) 05/2011 - 01/2006
2	Weight Gain 09/2010 - 01/2006
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2010 - 11/2005
2	Papilloma (Papillomatosis) 01/2010 - 09/2004
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 11/2019
1	Bacterial Vaginosis 11/2019
1	Atopic Dermatitis (Atopic Eczema) 11/2019
1	Gingivitis 11/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Weight Loss (Weight Reduction) 10/2017
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2017
1	Neuroblastoma 01/2017
1	Hepatitis B 01/2016

Drug/Important Bio-Agent (IBA)

42	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 05/2004
30	LigandsIBA 01/2019 - 09/2004
25	PPAR-betaIBA 07/2010 - 05/2004
12	PPAR alphaIBA 01/2014 - 01/2003
11	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2019 - 09/2004
10	(4- (((2- (3- fluoro- 4- (trifluoromethyl)phenyl)- 4- methyl- 1,3- thiazol- 5- yl)methyl)sulfanyl)- 2- methylphenoxy)acetic acidIBA 11/2011 - 11/2005
9	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2006
8	PPAR deltaIBA 04/2009 - 05/2004
7	LipidsIBA 10/2018 - 05/2004
6	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 12/2010 - 05/2006
5	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 02/2006
5	Pharmaceutical PreparationsIBA 02/2013 - 01/2003
4	Transcription Factors (Transcription Factor)IBA 10/2018 - 12/2008
4	Biological ProductsIBA 01/2018 - 09/2003
4	anthraceneIBA 07/2014 - 05/2004
4	nimesulide (Aulin)IBA 12/2010 - 01/2008
4	PPAR gammaIBA 11/2007 - 09/2004
3	Triglycerides (Triacylglycerol)IBA 01/2016 - 05/2004
3	AzoxymethaneIBA 01/2012 - 01/2008
3	Messenger RNA (mRNA)IBA 11/2011 - 01/2005
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 12/2010 - 05/2006
3	ProstaglandinsIBA 04/2009 - 05/2006
3	GW 501516IBA 09/2008 - 12/2007
3	CarcinogensIBA 09/2004 - 01/2003
2	GW 7647IBA 01/2021 - 01/2021
2	CytokinesIBA 01/2016 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 02/2013
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 07/2014 - 02/2014
2	Estrogen ReceptorsIBA 04/2014 - 02/2014
2	Bile Acids and Salts (Bile Acids)IBA 07/2013 - 01/2005
2	Dextrans (Dextran)FDA Link 01/2012 - 11/2007
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2012 - 11/2007
2	Sulindac (Copal)FDA LinkGeneric 11/2011 - 05/2006
2	Cyclin D1IBA 11/2011 - 10/2009
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2010 - 09/2007
2	beta CateninIBA 10/2009 - 11/2004
2	Prostaglandins EIBA 01/2008 - 05/2006
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2008 - 09/2007
2	Diethylhexyl Phthalate (DEHP)IBA 05/2006 - 01/2003
2	Ubiquitin CIBA 03/2005 - 05/2004
2	Stearoyl-CoA DesaturaseIBA 08/2004 - 12/2002
1	Amino Acids FDA Link 01/2020
1	PrebioticsIBA 11/2019
1	Chimeric Antigen ReceptorsIBA 10/2018
1	Phosphotransferases (Kinase)IBA 10/2018
1	NF-kappa B (NF-kB)IBA 01/2018
1	Choline (Choline Chloride)IBA 10/2017
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017
1	Citric Acid (Citrate)FDA LinkGeneric 01/2017
1	TOR Serine-Threonine KinasesIBA 01/2017
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	ArginaseIBA 01/2016
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2015
1	Transcription Factor 3IBA 11/2015

Therapy/Procedure

9	Chemoprevention 10/2017 - 09/2004
5	Therapeutics 10/2018 - 12/2011
2	Drug Therapy (Chemotherapy) 01/2017 - 11/2004
1	Precision Medicine 10/2018
1	Immunomodulation 10/2018
1	Transjugular Intrahepatic Portasystemic Shunt 01/2017